CORBF vs. FLGT, LFMD, CSTL, PSNL, INNV, CELC, FTRE, SBC, OMDA, and AUNA
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Fulgent Genetics (FLGT), LifeMD (LFMD), Castle Biosciences (CSTL), Personalis (PSNL), InnovAge (INNV), Celcuity (CELC), Fortrea (FTRE), SBC Medical Group (SBC), Omada Health (OMDA), and Auna (AUNA). These companies are all part of the "healthcare" industry.
Global Cord Blood vs. Its Competitors
Fulgent Genetics (NASDAQ:FLGT) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.
Fulgent Genetics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500.
Fulgent Genetics presently has a consensus target price of $24.00, indicating a potential upside of 24.55%. Given Fulgent Genetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Fulgent Genetics is more favorable than Global Cord Blood.
48.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Global Cord Blood has lower revenue, but higher earnings than Fulgent Genetics.
In the previous week, Fulgent Genetics had 3 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Fulgent Genetics and 0 mentions for Global Cord Blood. Fulgent Genetics' average media sentiment score of 1.19 beat Global Cord Blood's score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.
Global Cord Blood has a net margin of 0.00% compared to Fulgent Genetics' net margin of -13.94%. Global Cord Blood's return on equity of 0.00% beat Fulgent Genetics' return on equity.
Summary
Fulgent Genetics beats Global Cord Blood on 10 of the 14 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CORBF) was last updated on 7/12/2025 by MarketBeat.com Staff
Free CORBF Stock Alerts